Oppenheimer Reiterates Outperform (N/A) on Celgene (CELG)

By admin | 6 years ago

Celgene (NASDAQ: CELG)‘s stock had its “outperform (n/a)” rating restated by equities researchers at Oppenheimer (NYSE: OPY) in a report issued on Monday.

Shares of Celgene opened at 64.89 on Monday. Celgene has a one year low of $51.70 and a one year high of $80.42. The company has a market cap of $28.584 billion and a P/E ratio of 20.20.

Celgene last issued its quarterly earnings data on Thursday, April 26th. The company reported $1.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.13 by $0.05. The company’s revenue for the quarter was up 13.2% on a year-over-year basis. On average, analysts predict that Celgene will post $1.24 earnings per share next quarter.

Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note to investors on Friday, May 11st. They now have a $74.00 price target on the stock. Finally, analysts at UBS AG (NYSE: UBS) cut their EPS estimates on shares of Celgene in a research note on Friday. They now have a “buy” rating and a $85.00 price target on the stock. They previously had a $88.00 price target on the stock.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

About the author